<DOC>
	<DOCNO>NCT00140166</DOCNO>
	<brief_summary>Controlled study use orthomolecular approach ( Deutsch , Ananth , &amp; Ban , 1977 ) . Those do perform chronic schizophrenia population include bipolar schizoaffective patient . Both diagnostic group today consider benefit orthomolecular approach . Moreover , negative study high-dose niacin do patient otherwise give general counseling good diet describe . Therefore , proposal study control manner carefully define first onset schizophrenic patient use protocol advocate Osmond Hoffer ( 1962 ) . Patients enter study ill less 1 year first hospitalization .</brief_summary>
	<brief_title>Treatment Acute Schizophrenia With Vitamin Therapy</brief_title>
	<detailed_description>Controlled study use orthomolecular approach ( Deutsch , Ananth , &amp; Ban , 1977 ) . Those do perform chronic schizophrenia population include bipolar schizoaffective patient . Both diagnostic group today consider benefit orthomolecular approach . Moreover , negative study high-dose niacin do patient otherwise give general counseling good diet describe . Therefore , proposal study control manner carefully define first onset schizophrenic patient use protocol advocate Osmond Hoffer ( 1962 ) . Patients enter study ill less 1 year first hospitalization . Our Beersheba Mental Health Center hospitalization facility Southern Israel , population half million . There 2 thousand admission hospital yearly 100 admission diagnosis schizophrenia schizophreniform disorder first lifetime admission hospital first episode psychosis . Methods Study I - Open Pilot The pilot study carry exactly , except without control group . Results pilot evaluate continue control study , protocol modification present Helsinki Committee necessary . Ten patient study open pilot study . Study II - Controlled Study , Not Blind Inclusion exclusion criterion Patients accept study age 18-30 , admit diagnosis review study coordinator schizophrenia schizophreniform disorder DSM-IV . Since diagnosis schizophrenia may difficult early stage acute psychotic disease , case clinical diagnosis consistent suspicious schizophrenia ( inconsistent bipolar disorder ) even fulfill diagnostic criterion DSM-IV accept . Patients alcohol drug abuse last 6 month exclude . Patients significant physical illness include peptic ulcer , history hepatitis baseline abnormal liver function test exclude . Patients mental retardation exclude . Baseline screen do liver function ( include AST , bilirubin , alkaline phosphatase LDH ) blood glucose repeat 6 week . Elevations AST three fold lead drop patient study . Patients unlikely able continue study outpatient exclude . Patients admit study first lifetime psychiatric admission first episode psychosis history support mentally ill less one year . Procedure Patients enter program treat risperidone , 2-8mg daily physician 's discretion . They randomize accord predetermine random order vitamin regime Centrum forte . Doses risperidone lower clinically possible . Risperidone dose record weekly serve secondary outcome measure . A registered dietician meet patient weekly discourage refine sugar excess fat encourage regular fruit vegetable consumption . High protein breakfast emphasize . Fifteen patient start yearly three year . The vitamin regimen follow twice daily food : 1 . Ascorbic acid 1.5 g twice daily . 2 . 150 mg vitamin B6 twice daily 3 . Niacinamide 500 mg tablet , 3 tablet ( 1.5g ) twice daily food . 4 . Centrum Forte , one tablet morning food . The comparison group receive Centrum Forte per day . Outcome measure Patients rat Brief Psychiatric Rating Scale ( BPRS ) baseline weekly 6 month . All patient receive supportive psychotherapy hospitalization clinic follow-up . Discharged patient follow outpatient clinic Beersheba Mental Health Center physician plus dietician team dedicate study . Each patient follow six month . Outcome measure BPRS rating course half year , readmission , Global Clinical Assessment function end half year , risperidone dose . Skin test A blunt response dermal erythema niacin widely report schizophrenia , possible response might predict clinical response niacin treatment . All patient Horrobin niacin patch test ( Smesny et al. , 2003 ) admission study repeat 6 month continuous therapy . Niacin apply simultaneously four dilution ( 0.1 , 0.01 , 0.001 , 0.0001M ) 50microl ( approximately one drop standard eye-dropper ) skin inner side forearm use chambered plaster epicutaneous testing . After 90 second plaster remove . Skin reaction quantitated 3 minute interval 21 minute start 90 second removal plaster . Risks The risk high dose ascorbic acid review extensively refer dos 10g daily present dose 3g daily associate minimal risk eg diarrhea . Doses great 3gm daily cause increase ALT uric acid risk kidney stone substantiate ( Russel , 2005 ) . Niacin 3g daily widely use cholesterol lower agent ( Alpers , Stenson , &amp; Bier , 2002 ) associate minimal side effect danger eg , 5 % increase glucose , elevation liver enzyme exacerbation peptic ulcer , effect rarely ever see derivative nicotinamide ( Guyton , 2005 ) . The B-vitamins dos give would associate side effect . Alpers , D. H. , Stenson , W. F. , &amp; Bier , D. M. ( 2002 ) . Manual Nutritional Therapeutics . Philadelphia : Lippincott Williams &amp; Wilkins . Beauclair , L. , Vinogradov , S. , Riney , S. J. , Csernansky , J. G. , &amp; Hollister , L. E. ( 1987 ) . An adjunctive role ascorbic acid treatment schizophrenia ? J Clin Psychopharmacol , 7 ( 4 ) , 282-283 . Deutsch , M. , Ananth , J. V. , &amp; Ban , T. A . ( 1977 ) . Nicotinic acid treatment chronic hospitalize schizophrenic patient : placebo-controlled clinical study . Psychopharmacol Bull , 13 ( 3 ) , 21-23 . Guyton , J. R. ( 2005 ) . Hyperlimpprotenemias . In R. E. Rakel &amp; E. T. Bope ( Eds . ) , Conn 's Current Therapy 2005 ( pp . 688-694 ) . Pennsylvania : Elsevier/Saunders . Kanofsky , J. D. , &amp; Sandyk , R. ( 1992 ) . Antioxidants treatment schizophrenia . Int J Neurosci , 62 ( 1-2 ) , 97-100 . Kleijnen , J. , &amp; Knipschild , P. ( 1991 ) . Niacin vitamin B6 mental functioning : review control trial human . Biol Psychiatry , 29 ( 9 ) , 931-941 . Lerner , V. , Miodownik , C. , Kaptsan , A. , Cohen , H. , Loewenthal , U. , &amp; Kotler , M. ( 2002 ) . Vitamin B6 add-on treatment chronic schizophrenic schizoaffective patient : double-blind , placebo-controlled study . J Clin Psychiatry , 63 ( 1 ) , 54-58 . Levine , J. , Stahl , Z. , Sela , B . A. , Ruderman , V. , Shumaico , O. , Babushkin , I. , et al . ( revision ) . Homocysteine reduce strategy improve symptom chronic schizophrenia patient hyperhomocysteinemia . Osmond , H. , &amp; Hoffer , A . ( 1962 ) . Massive niacin treatment schizophrenia . Review nine-year study . Lancet , 1 , 316-319 . Russel , R. M. ( 2005 ) . Vitamine trace mineral deficiency excess . In D. L. Kasper , A. S. Favci , D. L. Lango , E. Braunwald , S. L. Hauser &amp; J. L. Jameson ( Eds . ) , Harrison 's Principles Internal Medicine ( 16th ed. , pp . 403-407 ) : McGraw Hill . Sandyk , R. , &amp; Kanofsky , J. D. ( 1993 ) . Vitamin C treatment schizophrenia . Int J Neurosci , 68 ( 1-2 ) , 67-71 . Smesny , S. , Berger , G. , Rosburg , T. , Riemann , S. , Riehemann , S. , McGorry , P. , et al . ( 2003 ) . Potential use topical niacin skin test early psychosis -- combined approach use optical reflection spectroscopy descriptive rating scale . J Psychiatr Res , 37 ( 3 ) , 237-247 . Smythies , J. R. ( 1996 ) . The role ascorbate brain : therapeutic implication . J R Soc Med , 89 ( 5 ) , 241.. Straw , G. M. , Bigelow , L. B. , &amp; Kirch , D. G. ( 1989 ) . Haloperidol reduce haloperidol concentration psychiatric rating schizophrenic patient treat ascorbic acid . J Clin Psychopharmacol , 9 ( 2 ) , 130-132 . Suboticanec , K. , Folnegovic-Smalc , V. , Korbar , M. , Mestrovic , B. , &amp; Buzina , R. ( 1990 ) . Vitamin C status chronic schizophrenia . Biol Psychiatry , 28 ( 11 ) , 959-966 . Suboticanec , K. , Folnegovic-Smalc , V. , Turcin , R. , Mestrovic , B. , &amp; Buzina , R. ( 1986 ) . Plasma level urinary vitamin C excretion schizophrenic patient . Hum Nutr Clin Nutr , 40 ( 6 ) , 421-428 . Vaughan , K. , &amp; McConaghy , N. ( 1999 ) . Megavitamin dietary treatment schizophrenia : randomise , control trial . Aust N Z J Psychiatry , 33 ( 1 ) , 84-88 .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<criteria>age 1830 schizophrenia schizophreniform disorder first psychiatric admission first episode psychosis mentally ill less one year alcohol drug abuse last 6 month significant physical illness mental retardation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>niacinamide</keyword>
</DOC>